Epilepsy is a chronic disease characterized by recurrent unprovoked seizures. Up to 30% of children with epilepsy will be refractory to standard anticonvulsant therapy, and those with epileptic encephalopathy can be particularly challenging to treat.
Sharing is an important part of cannabis culture. It’s especially common in recreational users, for whom the communal use of cannabis is a way of social interaction and even a social ritual.
Cannabis retailers have seen a similar trend, with many consumers choosing to make fewer trips to dispensaries, instead opting for larger, less frequent purchases as COVID-19 fears grip the country.
Cannabis-based medicines (CBMs) may offer relief from symptoms of disease; however, their additional cost needs to be considered alongside their effectiveness. We sought to review the economic costs and benefits of prescribed CBMs in any chronic illness, and the frameworks used for their economic evaluation. Prescribed CBMs are a potentially cost-effective add-on treatment for MS spasticity; however, this evidence is uncertain. Further investment in randomised trials with in-built economic evaluations is warranted for a wider range of clinical indications.